Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 64.48% is 34% above its 5-year average of 48.25%, near the high end of its 5-year range (-241.56%–71.33%).
0.35% below its 12-month average of 64.71%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 64.24%.
GROSS MARGIN
64.48%
GROSS MARGIN AVG TTM
64.71%
GROSS MARGIN AVG 3Y
59.25%
GROSS MARGIN AVG 5Y
48.25%
GROSS MARGIN AVG 10Y
55.02%
GROSS MARGIN AVG 15Y
53.23%
GROSS MARGIN AVG 20Y
51.17%
CURRENT VS TTM AVG
-0.35%
CURRENT VS 3Y AVG
+8.82%
CURRENT VS 5Y AVG
+33.64%
CURRENT VS 10Y AVG
+17.19%
CURRENT VS 15Y AVG
+21.14%
CURRENT VS 20Y AVG
+26.00%
SECTOR MEDIAN · HEALTHCARE
44.24%
median of 556 covered companies
CURRENT VS SECTOR MEDIAN
+45.75%
vs the sector median at left
BioLife Solutions, Inc.
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.71%
3Y Avg
59.25%
5Y Avg
48.25%
Market Cap
$1.87B
Gross Margin
78.67%
TTM Avg
83.63%
3Y Avg
79.97%
5Y Avg
53.31%
Market Cap
$1.85B
Gross Margin
9.22%
TTM Avg
11.32%
3Y Avg
13.89%
5Y Avg
14.07%
Market Cap
$1.93B
Gross Margin
-319.36%
TTM Avg
-798.46%
3Y Avg
-813.46%
5Y Avg
-704.28%
Market Cap
$1.83B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.96B
Gross Margin
70.49%
TTM Avg
67.64%
3Y Avg
66.50%
5Y Avg
65.90%
Market Cap
$1.81B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioLife Solutions, Inc. (BLFS) | $1.89B | 64.48% | 64.71% | 59.25% | 48.25% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | 78.67% | 83.63% | 79.97% | 53.31% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 9.22% | 11.32% | 13.89% | 14.07% |
| Absci Corporation (ABSI)vs › | $1.93B | -319.36% | -798.46% | -813.46% | -704.28% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.83B | 72.90% | 70.08% | 67.68% | 66.96% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | 70.49% | 67.64% | 66.50% | 65.90% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.81B | 76.47% | 79.35% | 79.86% | 39.87% |
| Immunome, Inc. (IMNM)vs › | $1.99B | 57.43% | 78.72% | 64.36% | 42.91% |
| AxoGen, Inc. (AXGN)vs › | $2.01B | 74.56% | 75.05% | 76.31% | 78.00% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.76B | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
64.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 64.24% |
| 2026-03-31 | 63.31% |
| 2025-12-31 | 67.48% |
| 2025-09-30 | 63.85% |
| 2025-06-30 | 64.64% |
| 2025-03-31 | 65.94% |
| 2024-12-31 | -241.56% |
| 2024-09-30 | 71.33% |
| 2024-06-30 | 66.99% |
| 2024-03-31 | 66.41% |
| 2023-12-31 | 28.26% |
| 2023-09-30 | 50.88% |
| 2023-06-30 | 37.71% |
| 2023-03-31 | 37.24% |
| 2022-12-31 | 31.57% |
| 2022-09-30 | 33.72% |
| 2022-06-30 | 35.38% |
| 2022-03-31 | 32.51% |
| 2021-12-31 | 16.53% |
| 2021-09-30 | 26.44% |
| 2021-06-30 | 40.54% |
| 2021-03-31 | 55.18% |
| 2020-12-31 | 54.14% |
| 2020-09-30 | 57.21% |
| 2020-06-30 | 54.65% |
| 2020-03-31 | 62.44% |
| 2019-12-31 | 49.98% |
| 2019-09-30 | 68.44% |
| 2019-06-30 | 70.78% |
| 2019-03-31 | 71.46% |
| 2018-12-31 | 68.66% |
| 2018-09-30 | 69.65% |
| 2018-06-30 | 70.32% |
| 2018-03-31 | 64.25% |
| 2017-12-31 | 58.71% |
| 2017-09-30 | 63.02% |
| 2017-06-30 | 62.59% |
| 2017-03-31 | 60.76% |
| 2016-12-31 | 60.71% |
| 2016-09-30 | 56.87% |
| 2016-06-30 | 56.14% |
| 2016-03-31 | 58.37% |
| 2015-12-31 | 62.63% |
| 2015-09-30 | 59.65% |
| 2015-06-30 | 54.69% |
| 2015-03-31 | 58.81% |
| 2015-01-31 | 59.76% |
| 2014-09-30 | 47.32% |
| 2014-06-30 | 45.00% |
| 2014-03-31 | 43.75% |
| 2013-12-31 | 40.20% |
| 2013-09-30 | 40.95% |
| 2013-06-30 | 35.56% |
| 2013-03-31 | 52.11% |
| 2012-12-31 | 36.69% |
| 2012-09-30 | 35.41% |
| 2012-06-30 | 41.52% |
| 2012-03-31 | 58.59% |
| 2011-12-31 | 56.46% |
| 2011-09-30 | 51.71% |
| 2011-06-30 | 53.61% |
| 2011-03-31 | 39.65% |
| 2010-12-31 | 35.98% |
| 2010-09-30 | 42.84% |
| 2010-06-30 | 41.39% |
| 2010-03-31 | 46.54% |
| 2009-12-31 | 52.49% |
| 2009-09-30 | 26.34% |
| 2009-06-30 | 20.86% |
| 2009-03-31 | 38.94% |
| 2008-12-31 | 0.01% |
| 2008-09-30 | 56.55% |
| 2008-06-30 | 18.20% |
| 2008-03-31 | 50.13% |
| 2007-12-31 | 0.01% |
| 2007-09-30 | 69.24% |
| 2007-06-30 | 63.23% |
| 2007-03-31 | 51.07% |
| 2006-12-31 | 0.02% |
| 2006-09-30 | 52.13% |
| 2006-06-30 | 41.11% |
| 2006-03-31 | 44.77% |
| 2005-12-31 | 42.42% |
| 2005-09-30 | 68.64% |
| 2005-06-30 | 72.99% |
| 2005-03-31 | 59.81% |
| 2004-12-31 | 1.67% |
| 2004-09-30 | 96.16% |
| 2004-06-30 | 93.95% |
| 2004-03-31 | 105.83% |
| 2003-12-31 | 100.00% |
| 2003-09-30 | 97.94% |
| 2003-06-30 | 92.26% |
| 2003-03-31 | 100.00% |
| 2002-12-31 | 100.00% |
| 2002-09-30 | 100.00% |
